Metformin

Metformin has been prescribed to hundreds of millions of people for type 2 diabetes since the 1950s. Its safety profile — accumulated across seven decades of population-scale use — is exceptional. What the longevity field recognized in the 2010s is that metformin's benefits appear to extend well beyond glycemic control into a broad anti-aging profile that may be independent of diabetes status entirely. The primary mechanism is AMPK activation. Metformin inhibits mitochondrial Complex I, leading to a transient reduction in ATP production that activates AMP-activated protein kinase — the master metabolic regulator that acts as a cellular low-energy sensor. AMPK activation produces a cascade of longevity-relevant effects: inhibition of mTOR (shifting cells toward maintenance over growth), reduced IGF-1 signaling, decreased reactive oxygen species production, enhanced autophagy, and improved insulin sensitivity (PMC5943638). This mechanistic breadth — touching nutrient sensing, mitochondrial function, proteostasis, and inflammation — gives metformin a legitimately strong case as a geroprotective agent. The epidemiological evidence is striking. A large-scale analysis published in 2026 (PMC12223363) found that type 2 diabetic women taking metformin had a 30% lower all-cause mortality risk before age 90 compared to matched controls. Multiple studies have shown that metformin-treated diabetics outlive non-diabetic controls who are not on metformin — a finding so counterintuitive it catalyzed the TAME (Targeting Aging with Metformin) trial, the first FDA-approved trial with aging as a primary endpoint. TAME results are anticipated to be landmark. For healthy non-diabetic biohackers, the calculus is more nuanced. Metformin's AMPK activation partially overlaps with, and may blunt, the benefits of exercise-induced AMPK signaling. Research suggests co-administration with exercise programs may attenuate some cardiovascular adaptations. Thoughtful users cycle metformin on rest days or separate use from training windows. Standard longevity dosing is 500–1500mg/day; the Extended Release formulation (metformin ER) reduces gastrointestinal side effects that affect 30% of users on immediate-release formulations.